https://www.selleckchem.com/products/cb-839.html
According to data from the American Cancer Society, cancer is one of the deadliest health problems globally. Annually, renal cell carcinoma (RCC) causes more than 100,000 deaths worldwide [1-4], posing an urgent need to develop effective treatments to increase patient survival outcomes. New therapies are expected to address a major factor contributing to cancer's resistance to standard therapies oncogenic heterogeneity. Gene expression can vary tremendously among different types of cancers, different patients of the same tumor type, and
Like
Comment
Share
